ArticlePloS one2015
Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 218 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
218 citing papers in PubMed, 5 syntheses or guidelines pooled it, 363 citations in OpenAlex.
- A systematic review of genetic ancestry as a risk factor for incidence of non-small cell lung cancer in the US.Frontiers in genetics · 2023Pooled it
- Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis.Molecular diagnosis & therapy · 2022Pooled it
- Racial and socioeconomic disparities in lung cancer screening in the United States: A systematic review.CA: a cancer journal for clinicians · 2021Pooled it
- Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases.BioMed research international · 2021Pooled it
- A comparative analysis of heterogeneity in lung cancer screening effectiveness in two randomised controlled trials.Nature communications · 2025Trial
- Chidamide plus envafolimab as subsequent treatment in advanced non-small cell lung cancer patients resistant to anti-PD-1 therapy: A multicohort, open-label, phase II trial with biomarker analysis.Cancer medicine · 2024Trial
- Trends in participant race and sex reporting in lung cancer phase III clinical trials.Cancer reports (Hoboken, N.J.) · 2023Trial
- Trial
- Lung cancer screening with low-dose spiral computed tomography: evidence from a pooled analysis of two Italian randomized trials.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2017Trial
- Obesity Promotes Lung Carcinogenesis Through Airway Immune Dysfunction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- Dual-layer spectral CT for predicting spread through air spaces in lung adenocarcinoma: a dual-center study.European radiology · 2026Article
- GSDME-mediated pyroptosis modulates the immunosuppressive microenvironment in lung adenocarcinoma.Acta pharmacologica Sinica · 2026Article
- Trends in the Overall Incidence and Mortality of Lung Cancer: An Extensive Longitudinal Study Utilizing the CDC WONDER Database 1999-2020.Thoracic cancer · 2026Article
- Effect Modification by Cofactors in the Impact of Body Mass Index Change on the Risk of Lung Cancer.Cancer science · 2026Article
- CEACAM7 Expression and DNA Methylation: Prognostic Biomarkers for Lung Adenocarcinoma in African Americans.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- Conditional dependence of the "male-SCC, female-ADC" teaching heuristic in lung cancer: shifts in exposure pathways and the need for pathology education reform.Frontiers in public health · 2026Article
- Bioinformatics analysis of DLGAP5 as a biomarker in lung adenocarcinoma: implications for immune infiltration and targeted therapy.Discover oncology · 2025Article
- Graph neural network model using radiomics for lung CT image segmentation.Scientific reports · 2025Article
- Computed tomography-based quantification of intra-tumoral heterogeneity for predicting treatment response to concurrent chemoradiotherapy in non-small cell lung cancer: a multicenter retrospective study.Translational cancer research · 2025Article
158 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundLung cancer (LC) incidence in the United States (US) continues to decrease but with significant differences by histology, gender and race. Whereas squamous, large and small cell carcinoma rates have been decreasing since the mid-80s, adenocarcinoma rates remain stable in males and continue to increase in females, with large racial disparities. We analyzed LC incidence trends by histology in the US with an emphasis on gender and racial differences.
methodsLC incidence rates from 1973-2010 were obtained from the SEER cancer registry. Age-adjusted incidence trends of five major histological types by gender and race were evaluated using joinpoint regression. Trends of LC histology and stage distributions from 2005-2010 were analyzed.
resultsUS LC incidence varies by histology. Squamous, large and small cell carcinoma rates continue to decrease for all gender/race combinations, whereas adenocarcinoma rates remain relatively constant in males and increasing in females. An apparent recent increase in the incidence of squamous cell carcinoma and adenocarcinoma since 2005 can be explained by a concomitant decrease in the number of cases classified as other non-small cell carcinoma. Black males continue to be disproportionally affected by squamous LCs, and blacks continue to be diagnosed with more advanced cancers than whites.
conclusionsLC incidence by histology continues to change over time. Additional variations are expected as screening becomes disseminated. It is important to continue to monitor LC rates to evaluate the impact of screening on current trends, assess the continuing benefits of tobacco control, and focus efforts on reducing racial disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.